Atossa Therapeutics Inc. (ATOS) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Atossa Therapeutics Inc. (NASDAQ: ATOS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.23 (-5.91% 1D, market cap $22.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ATOS ranks #796 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATOS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AYTU (Aytu BioPharma Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $21.5M) and BYSI (BeyondSpring Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $21.2M). Among the 5-stock peer group, ATOS leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).
Per ATOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001488039), Atossa Therapeutics Inc. generated $0 in revenue, -$34.8M in net income, and -$29.8M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 40.3 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ATOS currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.42) and Max Pain ($2.34) forces dealer call-delta covering toward $15.59.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Atossa Therapeutics Inc. (ATOS) dropped -5.91% to $2.23, trading at 4% of its 52-week range ($1.7 – $14.85). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today confirmed that
Under the terms of the Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, each share of Atossa common stock outstanding at the close of business on
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ATOS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ATOS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Atossa Therapeutics Inc. (ATOS) ranks #796 by composite RQD confidence (36/100, grade D-) and #824 by equity capitalization ($22.3M). Within this direct 5-issuer industry benchmark cohort, ATOS leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ATOS at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ATOS
ACTIVE
Atossa Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -5.91% | $22.3M | Benchmark Subject |
| AYTU Aytu BioPharma Inc. | D- | 41/100 | — | 69.0% | -35.0% | +0.51% | $21.5M | /aytu-vs-atos → |
| BYSI BeyondSpring Inc. | D- | 42/100 | — | — | -35.0% | -1.49% | $21.2M | /bysi-vs-atos → |
| TXMD TherapeuticsMD Inc. | D | 48/100 | — | — | -12.9% | +2.24% | $21.2M | /txmd-vs-atos → |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | D+ | 58/100 | — | — | — | +2.95% | $20.7M | /qntm-vs-atos → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atossa Therapeutics Inc. (ATOS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$34.8M, operating cash flow of -$29.8M, and free cash flow of -$29.8M (-41.5% YoY). On the balance sheet, ATOS closed FY2025 with $47.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$34.8M | -$29.8M | -$29.8M | $47.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$25.5M | -$21.0M | -$21.0M | $76.4M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$30.1M | -$20.9M | -$20.9M | — | — |
As of 2026-11-01, Atossa Therapeutics Inc. (NASDAQ: ATOS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.23 (-5.91% 1D, market cap $22.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ATOS ranks #796 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATOS carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AYTU (Aytu BioPharma Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $21.5M) and BYSI (BeyondSpring Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $21.2M). Among the 5-stock peer group, ATOS leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).
Per ATOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001488039), Atossa Therapeutics Inc. generated $0 in revenue, -$34.8M in net income, and -$29.8M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ATOS last traded at $2.23 (-5.91% on volume of 68,017 shares), positioning the stock -7.85% below its 50-day simple moving average ($2.42) and -43.54% below its 200-day simple moving average ($3.95). Across its 52-week range of $1.70 to $14.85, ATOS sits at the 4.0% percentile with a 14-day RSI of 40.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.95 to $2.51).
Why ATOS Stock dropped -5.91% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.